19.5. Analysis.
Comparison 19: VX‐659 (80 mg once daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo (F508del/MF), Outcome 5: Sweat chloride (change from baseline) (mmol/L)
Comparison 19: VX‐659 (80 mg once daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo (F508del/MF), Outcome 5: Sweat chloride (change from baseline) (mmol/L)